SCHEMBL3685348

SCHEMBL3685348

CN(C)c1ccc2c(S(=O)(=O)Cl)cccc2c1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.40
KDM4E B2RXH2 3/20 0.38
HTR6 P50406 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
CA2 P00918 2/20 0.36
CA1 P00915 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALDH1A1 P00352 2/20 0.34
TERT O14746 1/20 0.34
APP P05067 1/20 0.34
TSHR P16473 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30879534 1.00 NSD2 (0.40) NSD2KDM4EHTR6L3MBTL1CA2
SCHEMBL23630294 0.85 NSD2 (0.51) NSD2KDM4EHTR6L3MBTL1CA2
SCHEMBL29948294 0.85 NSD2 (0.51) NSD2KDM4EHTR6L3MBTL1CA2
SCHEMBL10408524 0.77 CA1 (0.42) KDM4EHTR6CA2CA1CA9
SCHEMBL4463997 0.76 TRPV4 (0.43) L3MBTL1CA2CA1CA9MAPT
SCHEMBL9418644 0.76 HTR6 (0.41) HTR6CA2CA1CA9LMNA
SCHEMBL30727424 0.76 TRPV4 (0.43) L3MBTL1CA2CA1CA9MAPT
SCHEMBL10408514 0.75 CA1 (0.41) KDM4EHTR6L3MBTL1CA2CA1
SCHEMBL8494394 0.75 PLAU (0.50) NSD2HTR6CA2CA1CA9
SCHEMBL5633017 0.75 CYP2A6 (0.41) HTR6CA2CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025129193-A1 GLYCOSYLTRANSFERASES AND RELATED METHODS NEW ENGLAND BIOLABS, INC. (US) 2025-06-19 WO disclosed
EP-3469401-B1 IMAGING TECHNOLOGIES UNIV REGENSBURG (DE) 2024-05-01 EP disclosed
EP-4360661-A1 NANOPARTICLES FOR MEDICAL IMAGING AND TREATMENT Universität Regensburg (DE) 2024-05-01 EP disclosed
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2023-01-26 US disclosed
US-11479766-B2 Methods for labeling a population of RNA molecules NEW ENGLAND BIOLABS, INC. (US) 2022-10-25 US disclosed
EP-3469401-A1 IMAGING TECHNOLOGIES Universitätsklinikum Regensburg (DE) 2019-04-17 EP disclosed
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules NEW ENGLAND BIOLABS, INC. (US) 2018-07-12 US disclosed
EP-3279699-A1 IMAGING TECHNOLOGIES Universitätsklinikum Regensburg (DE) 2018-02-07 EP disclosed
US-20160046981-A1 Compositions and Methods for the Transfer of a Hexosamine to a Modified Nucleotide in a Nucleic Acid NEW ENGLAND BIOLABS, INC. (US) 2016-02-18 US disclosed
US-9200260-B2 Compositions and methods for the transfer of a hexosamine to a modified nucleotide in a nucleic acid NEW ENGLAND BIOLABS, INC. (US) 2015-12-01 US disclosed
EP-0521985-B1 CHIMERIC ANTIBODIES WITH RECEPTOR BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION UNIV COLUMBIA (US) 1997-09-24 EP disclosed
WO-1997030089-A1 NOVEL ANTIBODY-CYTOKINE FUSION PROTEIN, AND METHODS OF MAKING AND USING THE SAME REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-08-21 WO disclosed
US-5512667-A Trifunctional intermediates for preparing 3'-tailed oligonucleotides DRUG ROYALTY LP1 (CA) 1996-04-30 US disclosed
US-5419966-A Solid support for synthesis of 3'-tailed oligonucleotides MICROPROBE CORPORATION (US) 1995-05-30 US disclosed
EP-0547142-A4 MICROPROBE CORP (US) 1995-01-18 EP disclosed
EP-0547142-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE EPOCH PHARMACEUTICALS, INC. (US) 1993-06-23 EP disclosed
EP-0521985-A4 CHIMERIC ANTIBODIES WITH RECEPTOR BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION 1993-03-24 EP disclosed
EP-0521985-A1 CHIMERIC ANTIBODIES WITH RECEPTOR BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION. UNIV COLUMBIA (US) 1993-01-13 EP disclosed
WO-1992003464-A1 SOLID SUPPORT SYNTHESIS OF 3'-TAILED OLIGONUCLEOTIDES VIA A LINKING MOLECULE MICROPROBE CORPORATION (US) 1992-03-05 WO disclosed
WO-1991014438-A1 CHIMERIC ANTIBODIES WITH RECEPTOR BINDING LIGANDS IN PLACE OF THEIR CONSTANT REGION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 1991-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180195061-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP NSD2 2681/4885KDM4E 1517/4885HTR6 3708/4885
US-11479766-B2 Methods for labeling a population of RNA molecules RNGTT, RNMT, MTAP NSD2 2681/4885KDM4E 1517/4885HTR6 3708/4885
US-20230022745-A1 Methods for Labeling a Population of RNA Molecules RNGTT, RNMT, MTAP NSD2 2681/4885KDM4E 1517/4885HTR6 3708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.